Edition:
United States

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

36.85USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$36.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
151,046
52-wk High
$49.55
52-wk Low
$10.65

Chart for

About

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializi... (more)

Overall

Beta: --
Market Cap(Mil.): $1,317.06
Shares Outstanding(Mil.): 35.74
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.64 15.49
EPS (TTM): -- -- --
ROI: -- -10.01 11.95
ROE: -- -35.77 15.94

BRIEF-MyoKardia Inc reports Q3 loss per share $0.42

* MyoKardia Inc reports third quarter 2017 financial results and operational progress

Nov 02 2017

BRIEF-MyoKardia expects to initiate next trial of MYK-491 in DCM patients by year-end

* MyoKardia Inc - ‍next trial of MYK-491 in DCM patients expected to initiate by year-end​

Sep 27 2017

BRIEF-MyoKardia announces pricing of public offering of common stock

* MyoKardia announces pricing of public offering of common stock

Aug 08 2017

BRIEF-MyoKardia announces proposed public offering of common stock

* Commenced a proposed underwritten public offering of 3.5 million shares of its common stock Source text for Eikon: Further company coverage:

Aug 07 2017

MyoKardia hits life high after encouraging heart drug data

Shares of MyoKardia Inc hit a record high on Monday after the company said its experimental drug for an inherited heart disease met the main goal in a small mid-stage study.

Aug 07 2017

MyoKardia hits life high after encouraging heart drug data

Aug 7 Shares of MyoKardia Inc hit a record high on Monday after the company said its experimental drug for an inherited heart disease met the main goal in a small mid-stage study.

Aug 07 2017

BRIEF-Myokardia reports Q2 loss per share $0.41

* Myokardia reports second quarter 2017 financial results and operational progress

Aug 07 2017

BRIEF-Myokardia files for offering of up to 9.2 shares of common stock by selling stockholders

* Myokardia Inc files for offering of up to 9.2 shares of common stock by the selling stockholders - sec filing

Jul 10 2017

Earnings vs. Estimates